CD8A and melanoma: While we were writing this manuscript, Palucka et al [24] published the results of a phase I clinical trial of a vaccine composed of DCs loaded with killed allogeneic melanoma cells which induced objective clinical responses and elicited MART-1 specific CD8+T cells in stage IV patients.